In October, the FDA released a new draft guidance outlining which Quality Management System (QMS) details must now be included in Premarket Approval (PMA) and Humanitarian Device Exemption (HDE) applications. This update aligns with the transition to the new Quality Management System Regulation (QMSR), effective February 2, 2026, which is based on ISO 13485:2016.
What does this mean for manufacturers?
- ISO 13485 remains the foundation—those already compliant with it will meet many of the requirements.
- The FDA now expects greater detail: submissions must comprehensively document, among other things, design controls, supplier management, process validations, and traceability.
- FDA-specific requirements:
- Mandatory compliance with additional FDA regulations (e.g., Unique Device Identification (UDI) per 21 CFR 830, Medical Device Reporting (MDR) per 21 CFR 803, Corrections & Removals per 21 CFR 806)
- FDA inspections will continue regardless of ISO certification
- Increased emphasis on traceability requirements
Conclusion:
The guidance does not introduce new principles, but it does raise transparency and documentation expectations. Manufacturers should review their QMS documentation specifically against FDA expectations—ISO 13485 compliance alone may no longer be sufficient.
Link: Quality Management System Information for Certain Premarket Submission Reviews | FDA
